{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T09:42:20Z","timestamp":1786268540528,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00204-026-04427-7","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:35:22Z","timestamp":1779269722000},"page":"4257-4273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of novel 2-[(8-hydroxyquinolin-7-yl)(phenyl)methylamino]benzoic acid derivatives for inhibiting the catalytic activity of botulinum neurotoxins type B and F: in silico, in vitro & in vivo evaluation"],"prefix":"10.1007","volume":"100","author":[{"given":"Surabhi","family":"Agnihotri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinita Chauhan","family":"Kushwah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3106-9994","authenticated-orcid":false,"given":"Ram Kumar","family":"Dhaked","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"issue":"3","key":"4427_CR1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/s0014-5793(98)00492-x","volume":"429","author":"M Adler","year":"1998","unstructured":"Adler M, Nicholson JD, Cornille F, Hackley BE Jr (1998) Efficacy of a novel metalloprotease inhibitor on botulinum neurotoxin B activity. FEBS Lett 429(3):234\u2013238. https:\/\/doi.org\/10.1016\/s0014-5793(98)00492-x","journal-title":"FEBS Lett"},{"issue":"21","key":"4427_CR2","doi-asserted-by":"publisher","first-page":"6637","DOI":"10.1021\/bi036278w","volume":"43","author":"R Agarwal","year":"2004","unstructured":"Agarwal R, Eswaramoorthy S, Kumaran D, Binz T, Swaminathan S (2004) Structural analysis of botulinum neurotoxin type E catalytic domain and its mutant Glu212\u2013>Gln reveals the pivotal role of the Glu212 carboxylate in the catalytic pathway. Biochemistry 43(21):6637\u20136644. https:\/\/doi.org\/10.1021\/bi036278w","journal-title":"Biochemistry"},{"issue":"7","key":"4427_CR3","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nsmb.1626","volume":"16","author":"R Agarwal","year":"2009","unstructured":"Agarwal R, Schmidt JJ, Stafford RG, Swaminathan S (2009) Mode of VAMP substrate recognition and inhibition of Clostridium botulinum neurotoxin F. Nat Struct Mol Biol 16(7):789\u2013794. https:\/\/doi.org\/10.1038\/nsmb.1626","journal-title":"Nat Struct Mol Biol"},{"key":"4427_CR4","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s00044-024-03272-6","volume":"33","author":"S Agnihotri","year":"2024","unstructured":"Agnihotri S, Kushwah VC, Bansal S, Vimal M, Saxena N, Dhaked RK (2024) Novel 2-[(8-hydroxyquinolin-7-yl)(phenyl)methylamino]benzoic acid analogs targeting the active site of botulinum neurotoxins: designing, synthesis, and biological evaluation. Med Chem Res 33:1625\u20131642. https:\/\/doi.org\/10.1007\/s00044-024-03272-6","journal-title":"Med Chem Res"},{"issue":"2","key":"4427_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1124\/jpet.111.180653","volume":"338","author":"FH Al-Saleem","year":"2011","unstructured":"Al-Saleem FH, Nasser Z, Olson RM, Cao L, Simpson LL (2011) Identification of the factors that govern the ability of therapeutic antibodies to provide post challenge protection against botulinum toxin: a model for assessing post challenge efficacy of medical countermeasures against agents of bioterrorism and biological warfare. J Pharmacol Exp Ther 338(2):503\u2013517. https:\/\/doi.org\/10.1124\/jpet.111.180653","journal-title":"J Pharmacol Exp Ther"},{"issue":"22","key":"4427_CR6","doi-asserted-by":"publisher","first-page":"4648","DOI":"10.1021\/jm0300680","volume":"46","author":"C Anne","year":"2003","unstructured":"Anne C, Turcaud S, Quancard J, Teffo F, Meudal H, Fourni\u00e9-Zaluski MC, Roques BP (2003) Development of potent inhibitors of botulinum neurotoxin type B. J Med Chem 46(22):4648\u20134656. https:\/\/doi.org\/10.1021\/jm0300680","journal-title":"J Med Chem"},{"issue":"8","key":"4427_CR7","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1001\/jama.285.8.1059","volume":"285","author":"SS Arnon","year":"2001","unstructured":"Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O\u2019Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, Tonat K, Working Group on Civilian Biodefense (2001) Botulinum toxin as a biological weapon: medical and public health management. JAMA 285(8):1059\u20131070. https:\/\/doi.org\/10.1001\/jama.285.8.1059","journal-title":"JAMA"},{"issue":"5","key":"4427_CR8","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1056\/NEJMoa051926","volume":"354","author":"SS Arnon","year":"2006","unstructured":"Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL (2006) Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 354(5):462\u2013471. https:\/\/doi.org\/10.1056\/NEJMoa051926","journal-title":"N Engl J Med"},{"issue":"8","key":"4427_CR9","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1021\/ol0603211","volume":"8","author":"GE Boldt","year":"2006","unstructured":"Boldt GE, Kennedy JP, Janda KD (2006) Identification of a potent botulinum neurotoxin A protease inhibitor using in situ lead identification chemistry. Org Lett 8(8):1729\u20131732. https:\/\/doi.org\/10.1021\/ol0603211","journal-title":"Org Lett"},{"issue":"1","key":"4427_CR10","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1021\/acs.jmedchem.6b01393","volume":"60","author":"PT Bremer","year":"2017","unstructured":"Bremer PT, Adler M, Phung CH, Singh AK, Janda KD (2017) Newly designed quinolinol inhibitors mitigate the effects of botulinum neurotoxin A in enzymatic, cell-based, and ex vivo assays. J Med Chem 60(1):338\u2013348. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b01393","journal-title":"J Med Chem"},{"issue":"3","key":"4427_CR11","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1021\/jm4012164","volume":"57","author":"D Cagli\u010d","year":"2014","unstructured":"Cagli\u010d D, Krutein MC, Bompiani KM, Barlow DJ, Benoni G, Pelletier JC, Reitz AB, Lairson LL, Houseknecht KL, Smith GR, Dickerson TJ (2014) Identification of clinically viable quinolinol inhibitors of botulinum neurotoxin A light chain. J Med Chem 57(3):669\u2013676. https:\/\/doi.org\/10.1021\/jm4012164","journal-title":"J Med Chem"},{"issue":"32","key":"4427_CR12","first-page":"680","volume":"50","author":"Centers for Disease Control and Prevention (CDC)","year":"2001","unstructured":"Centers for Disease Control and Prevention (CDC) (2001) Botulism outbreak associated with eating fermented food\u2013Alaska, 2001. Morb Mortal Wkly Rep 50(32):680\u2013682","journal-title":"Morb Mortal Wkly Rep"},{"issue":"10","key":"4427_CR13","first-page":"299","volume":"59","author":"Centers for Disease Control and Prevention (CDC)","year":"2010","unstructured":"Centers for Disease Control and Prevention (CDC) (2010) Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. Morb Mortal Wkly Rep 59(10):299","journal-title":"Morb Mortal Wkly Rep"},{"key":"4427_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.pep.2018.01.014","volume":"146","author":"R Chauhan","year":"2018","unstructured":"Chauhan R, Chauhan V, Rao MK, Chaudhary D, Bhagyawant S, Dhaked RK (2018) High level expression and immunochemical characterization of botulinum neurotoxin type F light chain. Protein Exp Purif 146:51\u201360. https:\/\/doi.org\/10.1016\/j.pep.2018.01.014","journal-title":"Protein Exp Purif"},{"key":"4427_CR16","doi-asserted-by":"publisher","first-page":"103297","DOI":"10.1016\/j.bioorg.2019.103297","volume":"92","author":"R Chauhan","year":"2019","unstructured":"Chauhan R, Chauhan V, Sonkar P, Vimal M, Dhaked RK (2019) Targeted 8-hydroxyquinoline fragment based small molecule drug discovery against neglected botulinum neurotoxin type F. Bioorg Chem 92:103297. https:\/\/doi.org\/10.1016\/j.bioorg.2019.103297","journal-title":"Bioorg Chem"},{"key":"4427_CR14","doi-asserted-by":"publisher","first-page":"106981","DOI":"10.1016\/j.toxicon.2022.106981","volume":"222","author":"R Chauhan","year":"2023","unstructured":"Chauhan R, Chauhan Kushwah V, Agnihotri S, Vimal M, Saxena N, Dhaked RK (2023) Designing, synthesis and evaluation of derived analogues of selected small molecule non-peptidic inhibitors against serotype BoNT\/ F. Toxicon 222:106981. https:\/\/doi.org\/10.1016\/j.toxicon.2022.106981","journal-title":"Toxicon"},{"key":"4427_CR17","unstructured":"Eitzen LT, Caudle MA (1993) Medical management of biological casualties. Publication No. 20170\u2009\u2013\u20095011). U.S. Army medical research institute of infectious diseases"},{"issue":"8","key":"4427_CR18","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1073\/pnas.0611213104","volume":"104","author":"LM Eubanks","year":"2007","unstructured":"Eubanks LM, Hixon MS, Jin W, Hong S, Clancy CM, Tepp WH, Baldwin MR, Malizio CJ, Goodnough MC, Barbieri JT, Johnson EA, Boger DL, Dickerson TJ, Janda KD (2007) An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc Natl Acad Sci USA 104(8):2602\u20132607. https:\/\/doi.org\/10.1073\/pnas.0611213104","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"4427_CR19","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1093\/cid\/cir550","volume":"53","author":"RP Fagan","year":"2011","unstructured":"Fagan RP, Neil KP, Sasich R, Luquez C, Asaad H, Maslanka S, Khalil W (2011) Initial recovery and rebound of type F intestinal colonization botulism after administration of investigational heptavalent botulinum antitoxin. Clin Infect Dis 53(9):e125\u2013e128. https:\/\/doi.org\/10.1093\/cid\/cir550","journal-title":"Clin Infect Dis"},{"issue":"1","key":"4427_CR20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1128\/mr.46.1.86-94.1982","volume":"46","author":"DM Gill","year":"1982","unstructured":"Gill DM (1982) Bacterial toxins: A table of lethal amounts. Microbiol Rev 46(1):86\u201394. https:\/\/doi.org\/10.1128\/mr.46.1.86-94.1982","journal-title":"Microbiol Rev"},{"issue":"3","key":"4427_CR21","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/infdis\/150.3.407","volume":"150","author":"CH Hatheway","year":"1984","unstructured":"Hatheway CH, Snyder JD, Seals JE, Edell TA, Lewis GE Jr (1984) Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E. J Infect Dis 150(3):407\u2013412. https:\/\/doi.org\/10.1093\/infdis\/150.3.407","journal-title":"J Infect Dis"},{"key":"4427_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-642-33570-9_1","volume":"364","author":"KK Hill","year":"2013","unstructured":"Hill KK, Smith TJ (2013) Genetic diversity within Clostridium botulinum serotypes, botulinum neurotoxin gene clusters and toxin subtypes. Curr Top Microbiol Immunol 364:1\u201320. https:\/\/doi.org\/10.1007\/978-3-642-33570-9_1","journal-title":"Curr Top Microbiol Immunol"},{"issue":"7","key":"4427_CR23","doi-asserted-by":"publisher","first-page":"685","DOI":"10.2174\/1568026615666150309150338","volume":"15","author":"G Kumar","year":"2015","unstructured":"Kumar G, Swaminathan S (2015) Recent developments with metalloprotease inhibitor class of drug candidates for botulinum neurotoxins. Curr Top Med Chem 15(7):685\u2013695. https:\/\/doi.org\/10.2174\/1568026615666150309150338","journal-title":"Curr Top Med Chem"},{"issue":"18","key":"4427_CR24","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1039\/c2cc17158a","volume":"48","author":"G Kumar","year":"2012","unstructured":"Kumar G, Agarwal R, Swaminathan S (2012) Discovery of a fluorene class of compounds as inhibitors of botulinum neurotoxin serotype E by virtual screening. Chem Commun 48(18):2412\u20132414. https:\/\/doi.org\/10.1039\/c2cc17158a","journal-title":"Chem Commun"},{"issue":"3","key":"4427_CR25","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.coph.2004.12.006","volume":"5","author":"C Montecucco","year":"2005","unstructured":"Montecucco C, Molg\u00f3 J (2005) Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol 5(3):274\u2013279. https:\/\/doi.org\/10.1016\/j.coph.2004.12.006","journal-title":"Curr Opin Pharmacol"},{"key":"4427_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.toxicon.2015.02.012","volume":"98","author":"VA Montgomery","year":"2015","unstructured":"Montgomery VA, Ahmed SA, Olson MA, Mizanur RM, Stafford RG, Roxas-Duncan VI, Smith LA (2015) Ex vivo inhibition of Clostridium botulinum neurotoxin types B, C, E, and F by small molecular weight inhibitors. Toxicon 98:12\u201319. https:\/\/doi.org\/10.1016\/j.toxicon.2015.02.012","journal-title":"Toxicon"},{"issue":"3","key":"4427_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1348-0421.1995.tb02184.x","volume":"39","author":"K Oguma","year":"1995","unstructured":"Oguma K, Fujinaga Y, Inoue K (1995) Structure and function of Clostridium botulinum toxins. Microbiol Immunol 39(3):161\u2013168. https:\/\/doi.org\/10.1111\/j.1348-0421.1995.tb02184.x","journal-title":"Microbiol Immunol"},{"issue":"4","key":"4427_CR28","doi-asserted-by":"publisher","first-page":"e10129","DOI":"10.1371\/journal.pone.0010129","volume":"5","author":"YP Pang","year":"2010","unstructured":"Pang YP, Davis J, Wang S, Park JG, Nambiar MP, Schmidt JJ, Millard CB (2010) Small molecules showing significant protection of mice against botulinum neurotoxin serotype A. PLoS ONE 5(4):e10129. https:\/\/doi.org\/10.1371\/journal.pone.0010129","journal-title":"PLoS ONE"},{"issue":"2","key":"4427_CR29","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1124\/pr.116.012658","volume":"69","author":"M Pirazzini","year":"2017","unstructured":"Pirazzini M, Rossetto O, Eleopra R, Montecucco C (2017) Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev 69(2):200\u2013235. https:\/\/doi.org\/10.1124\/pr.116.012658","journal-title":"Pharmacol Rev"},{"issue":"9","key":"4427_CR30","doi-asserted-by":"publisher","first-page":"528","DOI":"10.3390\/toxins11090528","volume":"11","author":"C Rasetti-Escargueil","year":"2019","unstructured":"Rasetti-Escargueil C, Popoff MR (2019) Antibodies and vaccines against botulinum toxins: available measures and novel approaches. Toxins 11(9):528. https:\/\/doi.org\/10.3390\/toxins11090528","journal-title":"Toxins"},{"issue":"8","key":"4427_CR31","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1128\/AAC.00141-09","volume":"53","author":"V Roxas-Duncan","year":"2009","unstructured":"Roxas-Duncan V, Enyedy I, Montgomery VA, Eccard VS, Carrington MA, Lai H, Gul N, Yang DC, Smith LA (2009) Identification and biochemical characterization of small-molecule inhibitors of Clostridium botulinum neurotoxin serotype A. Antimicrob Agents Chemother 53(8):3478\u20133486","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"4427_CR32","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1023\/a:1020687430927","volume":"18","author":"Y Sagane","year":"1999","unstructured":"Sagane Y, Watanabe T, Kouguchi H, Sunagawa H, Inoue K, Fujinaga Y, Oguma K, Ohyama T (1999) Dichain structure of botulinum neurotoxin: identification of cleavage sites in types C, D, and F neurotoxin molecules. J Protein Chem 18(8):885\u2013892. https:\/\/doi.org\/10.1023\/a:1020687430927","journal-title":"J Protein Chem"},{"issue":"32","key":"4427_CR33","doi-asserted-by":"publisher","first-page":"23784","DOI":"10.1016\/S0021-9258(20)80452-9","volume":"268","author":"G Schiavo","year":"1993","unstructured":"Schiavo G, Rossetto O, Catsicas S, Polverino de Laureto P, DasGupta BR, Benfenati F, Montecucco C (1993a) Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E. J Biol Chem 268(32):23784\u201323787. https:\/\/doi.org\/10.1016\/S0021-9258(20)80452-9","journal-title":"J Biol Chem"},{"issue":"16","key":"4427_CR34","doi-asserted-by":"publisher","first-page":"11516","DOI":"10.1016\/S0021-9258(19)50230-7","volume":"268","author":"G Schiavo","year":"1993","unstructured":"Schiavo G, Shone CC, Rossetto O, Alexander FC, Montecucco C (1993b) Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP\/synaptobrevin. J Biol Chem 268(16):11516\u201311519. https:\/\/doi.org\/10.1016\/S0021-9258(19)50230-7","journal-title":"J Biol Chem"},{"issue":"10","key":"4427_CR35","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1021\/bi0477642","volume":"44","author":"JJ Schmidt","year":"2005","unstructured":"Schmidt JJ, Stafford RG (2005) Botulinum neurotoxin serotype F: identification of substrate recognition requirements and development of inhibitors with low nanomolar affinity. Biochemistry 44(10):4067\u20134073. https:\/\/doi.org\/10.1021\/bi0477642","journal-title":"Biochemistry"},{"issue":"28","key":"4427_CR36","doi-asserted-by":"publisher","first-page":"6226","DOI":"10.1039\/c5cc00677e","volume":"51","author":"H Seki","year":"2015","unstructured":"Seki H, Xue S, Hixon MS, Pellett S, Remes M, Johnson EA, Janda KD (2015) Toward the discovery of dual inhibitors for botulinum neurotoxin A: concomitant targeting of endocytosis and light chain protease activity. Chem Commun 51(28):6226\u20136229. https:\/\/doi.org\/10.1039\/c5cc00677e","journal-title":"Chem Commun"},{"issue":"8","key":"4427_CR37","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1086\/444507","volume":"41","author":"J Sobel","year":"2005","unstructured":"Sobel J (2005) Botulism. Clin Infect Dis 41(8):1167\u20131173. https:\/\/doi.org\/10.1086\/444507","journal-title":"Clin Infect Dis"},{"key":"4427_CR38","doi-asserted-by":"publisher","unstructured":"Sonkar P, Kushwah VC, Agnihotri S, Disoriya D, Vimal M, Dhaked RK (2025) Targeting the enzymatic site of botulinum neurotoxin type E with 8-hydroxyquinolinol\u2013based inhibitors: in silico, in vitro, and in vivo evaluation. Drug Dev Res 86:e70148. https:\/\/doi.org\/10.1002\/ddr.70148","DOI":"10.1002\/ddr.70148"},{"issue":"1","key":"4427_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2332-0877.1000351","volume":"6","author":"C Vieni","year":"2018","unstructured":"Vieni C, McGillick BE, Kumaran D, Eswaramoorthy S, Kandavelu P, Swaminathan S (2018) Structure based discovery of pan active botulinum neurotoxin inhibitors. J Infect Dis Therapy 6(1):1\u20138. https:\/\/doi.org\/10.4172\/2332-0877.1000351","journal-title":"J Infect Dis Therapy"},{"issue":"20","key":"4427_CR40","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1016\/j.bmc.2016.07.031","volume":"24","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, McGillick BE, Teng YG, Haranahalli K, Ojima I, Swaminathan S, Rizzo RC (2016) Identification of small molecule inhibitors of botulinum neurotoxin serotype E via footprint similarity. Bioorg Med Chem 24(20):4875\u20134889. https:\/\/doi.org\/10.1016\/j.bmc.2016.07.031","journal-title":"Bioorg Med Chem"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-026-04427-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-026-04427-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-026-04427-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T09:31:38Z","timestamp":1786267898000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-026-04427-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4427"],"URL":"https:\/\/doi.org\/10.1007\/s00204-026-04427-7","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"12 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No human experiments were involved. However, approval for animal experiments was taken by the Institutional Animal Ethics Committee of the Institute (DRDE, Gwalior), mentioned in the Materials & Methods section.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}